Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients
NCT04224402Phase 2Completed
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in pancreatic cancer (PC). Started Jan 2020; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04224402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224402.